Prazant
6-(Difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 4679.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Activo Health (Pty) Ltd | Prazant | 20 | 500078 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Prazant 20 EACH TABLET CONTAINS PANTOPRAZOLE(AS SODIUM SESQUIHYDRATE) 20,0 mg | 20 | 50007850/11.4.3/0078 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Pantoprazole
- except when intended for the temporary short-term relief of heartburn and hyperacidity, subject to:
- a maximum daily dose of 20 milligrams (S2); and
- a maximum treatment period of 14 days. (S2)
Consolidated Schedules 06 July 2026, lines 7479 to 7482
S2: Pantoprazole
- when intended for the temporary short-term relief of heartburn and hyperacidity, subject to:
- maximum daily dose of 20 milligrams
- maximum treatment period of 14 days. (S4)
Consolidated Schedules 06 July 2026, lines 2482 to 2486
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.